

*The Swedish version of the emission notice is the original version and if any differences exist, the Swedish version prevail.
A translation of the full text can be requested by e-mail to: info@panion-animalhealth.com*

The Board of Panion Animal Health AB has decided to carry out a rights issue of units worth approximately SEK 9.2 million

Background

In January 2018, Panion completed a convertible issue of MSEK 9 directed to Yorkville Advisors Global (“Yorkville”) and a convertible issue of 0.5 MSEK directed to Dividend Sweden. Through the completed convertible issues, Panion was able to secure the Company’s capital requirements for the coming years.

The company now wants to give its existing shareholders the opportunity to subscribe for shares on similar terms to Yorkville and Dividend Sweden. The Board of Panion has therefore decided to implement a unit issue with preference for existing shareholders of a total of approximately SEK 9.2 million.

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion’s CEO, Anja E. H. Holm, for publication on May 4 2018.

For further information, please contact:

Anja E. H. Holm, CEO | +45-22 94 66 00
anja.holm@panion-animalhealth.com

Panion Animal Health AB

Frykholmmsgatan 11, 281 31 Hässleholm, Sweden
info@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB’s technology and platform. Panion Animal Health AB is listed at AktieTorget.

[linkedin.com/company/panion-animalhealth](https://www.linkedin.com/company/panion-animalhealth) 
twitter.com/panionanihealth 
panion-animalhealth.com/newsletter 
panion-animalhealth.com 